The Texas Medication Algorithm Project
The Journal of Clinical PsychiatryPublished 15 March 1999
M. Lynn Crismon, Madhukar H. Trivedi, Teresa A. Pigott, A. John Rush, Robert M. A. Hirschfeld, David A. Kahn
Citations248
SJR quartileQ1
SJR score1.49
SNIP1.38
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
These algorithms serve as the initial foundation for the development and implementation of medication treatment algorithms for patients treated in public mental health systems.
Abstract
These algorithms serve as the initial foundation for the development and implementation of medication treatment algorithms for patients treated in public mental health systems. Specific issues related to adaptation, implementation, feasibility testing, and evaluation of outcomes with the pharmacotherapeutic algorithms will be described in future articles.
Keywords
MedicineEconomics, Econometrics and FinanceHealth Professions
Medical Entomology and ZoologyPsychopharmacology: The Fourth Generation of Progress
2,988 Citations1995Floyd E. Bloom, David J. Kupfer
Annual Review of Public HealthWords Without Action? The Production, Dissemination, and Impact of Consensus Recommendations
305 Citations1991Jonathan Lomas
The review describes the decision points in the production process for consensus recommendations as a start on the development of a set of recognized standards, and offers a critical appraisal of the various methodological choices available at each decision point.
American Journal of PsychiatryEarly nonresponse to fluoxetine as a predictor of poor 8-week outcome
177 Citations1995Andrew A. Nierenberg, Nancy E. McLean +4 more
The proportion of patients with no response to antidepressant treatment by 4 or 6 weeks who responded by week 8 was substantially less than that for subjects who had at least a partial response.
Clinical PharmacokineticsAntidepressant Drug Interactions and the Cytochrome P450 System
150 Citations1995Larry Ereshefsky, Cara Riesenman +1 more
The extent of the in vivo interaction between the SSRIs and tricyclic antidepressants mirrors to a large extent their in vitro inhibitory potencies against CYP2D6 and other isoenzyme systems, especially if one takes into account pharmacokinetic factors.
PubMedEvolutionary trends in the pharmacotherapeutic management of depression.
103 Citations1994Charles B. Nemeroff
Advances in knowledge about the prevalence, risks, and course of depression in the general population, the elderly, and patients with comorbid medical illnesses and about the biological basis of depression are reviewed.
PubMedTexas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms.
95 Citations1998Dennis A. Gilbert, Kenneth Z. Altshuler +5 more
PubMedInitial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants.
84 Citations1996Gregory E. Simon, M VonKorff +5 more
Archives of General PsychiatryClinical Practice Guidelines
71 Citations1993A. John Rush
This commentary highlights the conceptual and scientific issues that surrounded the development of clinical practice guidelines for primary care providers that address the detection, diagnosis, and treatment of depression and speculate on their potential practical impact, particularly on psychiatry.
The British Journal of PsychiatryWho Responds to Electroconvulsive Therapy?
69 Citations1996Christina Sobin, Joan Prudic +3 more
ECT is a viable treatment option for patients with major depression regardless of the presence or absence of psychosis, retardation and/or agitation, and the findings cast doubt on the utility of these depression subtypes in predicting ECT response.
American Journal of Health-System PharmacyNefazodone: A new Antidepressant
61 Citations1995View L. Ellingrod, Paul J. Perry
Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyRational Drug Use in the Treatment of Depression
43 Citations1997Lawrence J. Cohen
Choosing a drug that is effective, tolerable, and convenient will improve the likelihood of achieving and maintaining a full remission of unipolar depression and decrease the morbidity and mortality of this very treatable disease.
PubMedFrom scientific knowledge to the clinical practice of psychopharmacology: can the gap be bridged?
38 Citations1995A. John Rush, Robert F. Prien
The nature and types of information and syntheses relevant to the strategic and tactical decisions required in the treatment of depression with medication, and the relationship between research efforts and the information needed by clinicians are examined are examined.
Annals of Clinical PsychiatryAugmentation with Buspirone: A Review
30 Citations1995Kenneth Harvey, Richard Balon
This work reviews the literature supporting the potential use of buspirone as an augmenting agent and indicates that it may prove to be a useful agent for augmentation of other psychotropic medications in these disorders.
Psychiatric AnnalsMedication Resistance, Response to ECT, and Prevention of Relapse
18 Citations1994Joan Prudic, Harold A. Sackeïm +1 more
Annals of PharmacotherapyA Critical Review of Selected Pharmacoeconomic Analyses of Antidepressant Therapy
18 Citations1999Therese Conner, M. Lynn Crismon +1 more
The economic aspects of treating depression are becoming more frequently evaluated as newer antidepressant medications become available and as healthcare entities attempt to address increasing costs.
American Journal of Health-System PharmacyDevelopment of ASHP therapeutic guidelines
8 Citations1995Leslie R. Dotson, David R. Witmer